ARB Clinical Trials

95 recruitingLast updated: July 25, 2026

There are 95 actively recruiting arb clinical trials across 46 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, New York, New York, United States. Updated daily from ClinicalTrials.gov.


ARB Trials at a Glance

95 actively recruiting trials for arb are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 23 trials, with the heaviest enrollment activity in Houston, Shanghai, and New York. Lead sponsors running arb studies include Bayer, Jian Chen, and Baylor College of Medicine.

Treatments under study

About ARB Clinical Trials

Looking for clinical trials for ARB? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ARB trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ARB clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 95 trials

Recruiting
Phase 2

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+3 more
Chinese PLA General Hospital30 enrolled1 locationNCT06471738
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Solid Tumors Harboring MET Amplification
AbbVie100 enrolled35 locationsNCT07196644
Recruiting
Phase 1Phase 2

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals40 enrolled7 locationsNCT07468071
Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Bayer150 enrolled76 locationsNCT04142437
Recruiting
Phase 2

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Shanghai Junshi Bioscience Co., Ltd.35 enrolled2 locationsNCT07518160
Recruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
Bayer100 enrolled1 locationNCT04945330
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069
Recruiting
Not Applicable

Neural and Metabolic Factors in Carbohydrate Reward

Carbohydrate Metabolism
Virginia Polytechnic Institute and State University64 enrolled1 locationNCT06053294
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer104 enrolled10 locationsNCT06659341
Recruiting

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

Stem Cell TransplantationPediatric RelapsedGemcitabine+5 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT07662018
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Solid TumorsHGGCancer Harboring BRAF Alterations+1 more
Fore Biotherapeutics254 enrolled70 locationsNCT05503797
Recruiting
Early Phase 1

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Plasmablastic LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell Lymphoma+2 more
AIDS Malignancy Consortium15 enrolled8 locationsNCT04139304
Recruiting

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

GliomasGlioma Glioblastoma MultiformeGliomas Harboring IDH1 and/or IDH2 Mutations+3 more
Xiangya Hospital of Central South University500 enrolled1 locationNCT07608003
Recruiting

Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study

bloodstream infectionSepsisPneumonia+1 more
Sichuan Provincial People's Hospital200 enrolled1 locationNCT07601711
Recruiting
Phase 1Phase 2

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

Healthy ParticipantsSarbecovirus
SK Bioscience Co., Ltd.368 enrolled2 locationsNCT07280858
Recruiting
Phase 1Phase 2

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn+1 more
iECURE, Inc.20 enrolled12 locationsNCT06255782
Recruiting
Phase 1

A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Marburg Virus Disease
International AIDS Vaccine Initiative112 enrolled2 locationsNCT07425821
Recruiting
Phase 1Phase 2

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

ARBBVMDAutosomal-Dominant Bestrophinopathy+1 more
Opus Genetics, Inc10 enrolled4 locationsNCT07185256
Recruiting

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

COVID19Influenza vaccinationARB+3 more
Consorci Sanitari de Terrassa3,000 enrolled1 locationNCT04367883